AMI Asset Management Corp Grows Stock Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

AMI Asset Management Corp raised its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 50.3% during the first quarter, Holdings Channel.com reports. The fund owned 77,688 shares of the company’s stock after purchasing an additional 26,010 shares during the quarter. AMI Asset Management Corp’s holdings in Kiniksa Pharmaceuticals International were worth $1,725,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of KNSA. Braidwell LP increased its position in shares of Kiniksa Pharmaceuticals International by 19.3% in the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company’s stock valued at $68,289,000 after acquiring an additional 557,934 shares during the period. JPMorgan Chase & Co. increased its position in shares of Kiniksa Pharmaceuticals International by 138.9% during the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company’s stock valued at $9,451,000 after buying an additional 277,827 shares during the period. Millennium Management LLC increased its position in shares of Kiniksa Pharmaceuticals International by 50.9% during the fourth quarter. Millennium Management LLC now owns 779,672 shares of the company’s stock valued at $15,422,000 after buying an additional 263,146 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter valued at about $3,955,000. Finally, Hudson Bay Capital Management LP increased its position in shares of Kiniksa Pharmaceuticals International by 150.0% during the fourth quarter. Hudson Bay Capital Management LP now owns 225,000 shares of the company’s stock valued at $4,450,000 after buying an additional 135,000 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on KNSA shares. Jefferies Financial Group boosted their price target on shares of Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, April 29th. Wedbush reiterated an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, April 16th. Citigroup started coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, March 13th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “buy” rating in a research report on Saturday, June 14th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals International has an average rating of “Buy” and a consensus price target of $38.80.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, insider Ross Moat sold 18,259 shares of the company’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $20.29, for a total value of $370,475.11. Following the transaction, the insider now owns 9,415 shares in the company, valued at approximately $191,030.35. This represents a 65.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Barry D. Quart sold 8,212 shares of the company’s stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $30.36, for a total transaction of $249,316.32. Following the completion of the transaction, the director now owns 12,546 shares in the company, valued at approximately $380,896.56. This represents a 39.56% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 440,863 shares of company stock worth $12,101,029. Corporate insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ:KNSA opened at $28.38 on Thursday. Kiniksa Pharmaceuticals International, plc has a one year low of $17.38 and a one year high of $30.69. The company’s 50-day simple moving average is $26.47 and its 200 day simple moving average is $22.54. The firm has a market capitalization of $2.07 billion, a P/E ratio of -113.52 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative net margin of 3.52% and a negative return on equity of 3.83%. The business had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. During the same quarter in the previous year, the firm posted ($0.25) earnings per share. Kiniksa Pharmaceuticals International’s quarterly revenue was up 72.5% on a year-over-year basis. On average, equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.